BioSpace News Archive

Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and first nine months of 2019 on November 5, 2019 after the close of the U.S. financial markets.

Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today presented a poster showing preclinical data supporting HPN328 as a treatment for small cell lung cancer (SCLC) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting in Boston.

Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, announced today the presentation of preclinical data of TP-1287, an investigational oral cyclin-dependent kinase 9 (CDK9) inhibitor, in castration-sensitive and resistant prostate cancer models and TP-1454, an investigational small-molecule pyruvate kinase M2 isoform (PKM2) activator, in colorectal cancer models

Securian Financial has awarded $10,000 to Phenomix Sciences, a Rochester, Minn.-based biomedical startup company, as the 2019 winner of a Securian Financial-sponsored award for innovation that shapes the future of financial services or life insurance through technology.

A new research study recently published as an “In Press” article in the Journal of Antivirals & Antiretrovirals [Volume 11, Issue 3, 2019] concludes that “phytomedical compounds, such as the cardenolide oleandrin, may one day represent a cost-effective therapeutic strategy to help combat enveloped virus infections in developing countries with limited access to modern antivirals.”

As people are living longer, more elderly patients are being diagnosed with age-related colon cancer, making it of increasing concern to the medical community.

Dr. Sanjay Basu and Dr. Rajiv Narayanaswamy, in conjunction with Stanford Medical School, recently released an article in an August issue of Medical Care that addresses social determinant health factors in the formation of uncontrolled type 2 diabetes mellitus The research is based on terabytes of area level data and claims data on over 1 million patients with Type 2 Diabetes Mellitus.

ValGenesis, Inc., a market leader in Enterprise Validation Lifecycle Management Solutions (VLMS), today announced a technology partnership with T-Systems North America in its effort to help Life Science sector’s transformation to Industrial Internet of Things (IIoT) Technology, which is becoming extremely critical in pharmaceutical and biotech manufacturing where sub-optimal environmental conditions have often lead to noncompliance.

BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2019 earnings on Tuesday, November 5 at 4:00 PM Eastern Time.

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its second quarter fiscal year 2020, ended September 30, 2019, at 4:15pm Eastern time on Friday, November 1, 2019.